Canon U.S.A. announced Thursday it has made a strategic investment in Ottawa-based Spartan Bioscience Inc. to fund research and development of new diagnostic testing products.
Canon’s wholly-owned subsidiary, Canon BioMedical Inc. is looking into ways it can work with Spartan on other products like rapid genetic testing.
“We are excited to continue our efforts as we move into new markets for rapid genetic testing,” Spartan CEO Paul Lem said in a statement. “Working with Canon will help accelerate our progress in the future.”
OBJ360 (Sponsored)
How to mitigate AI legal risks by asking the right questions
Does AI hallucinate? According to local employment law expert Zoriana Priadka of Emond Harnden, it does. Find out how to mitigate your risk as an employer.
DaaS: The mobile device management solution you never heard of
DaaS or “Device as a service” is a revolutionary communications strategy for businesses that rely on mobile devices to connect their employees, and it’s offered by a company an hour’s
Seymour Liebman, who currently sits on Canon BioMedical’s board of directors will also join Spartan’s board.
“Spartan’s goals align with our mission to provide enhanced diagnostic testing systems that can help improve human health worldwide,” Mr. Liebman said in a statement.
Terms of the investment were not disclosed.